MedTrace Logo

Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?

NCT00206986 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-12-20

No results posted yet for this study

Summary

The investigators want to try to improve information processing in schizophrenic patients via pharmacological intervention. The hypothesis is that decreased noradrenergic activity will normalize information processing (PPI, P50 gating, P300, and mismatch negativity) in patients with schizophrenia.

Conditions

Interventions

DRUG

clonidine

Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication

DRUG

clonidine

0.15 mg of clonidine will be administered to 20 healthy male volunteers

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Lundbeck Foundation

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • Birte Glenthoj

    lead OTHER

Principal Investigators

  • Birte Glenthoj, MD, DMSc. · Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychaitric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Denmark

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206986 on ClinicalTrials.gov